Jeremy Lee Stanek, MD
Sports Medicine · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Stanek’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A158198 · Current
Licensed to practise in California · since 2018 · expires 2028-08-31 · University of Missouri-Columbia School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$146,819
Medicare paid this office $146,819 for 644 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 263 | $37,246 | $97 |
| Return visit (30+ min) | 217 | $31,656 | $108 |
| New patient visit (45+ min) | 182 | $24,027 | $132 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 30 | $13,839 | None |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 48 | $4,743 | $67 |
See all 21 services
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 263 | $37,246 | $97 |
| Return visit (30+ min) | 217 | $31,656 | $108 |
| New patient visit (45+ min) | 182 | $24,027 | $132 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 30 | $13,839 | None |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 48 | $4,743 | $67 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 22 | $2,642 | $102 |
| Long return visit (40+ min) | 14 | $2,427 | $152 |
| New patient visit (60+ min) | 12 | $2,393 | $199 |
| Short return visit (20+ min) | 27 | $2,155 | $77 |
| Ultrasonic guidance for needle placement | 52 | $1,660 | $24 |
| Aspiration and/or injection of fluid from small joint using ultrasound guidance | 19 | $1,598 | $61 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 231 | $1,290 | None |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 42 | $1,275 | $28 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 69 | $1,098 | $15 |
| Injection into tendon or ligament | 19 | $913 | $38 |
| Injection of trigger points, 1-2 muscles | 14 | $760 | $45 |
| Aspiration and/or injection of fluid from large joint | 16 | $749 | $42 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 11 | $547 | $36 |
| Fluoroscopic guidance for needle placement | 11 | $310 | $24 |
| Injection, ropivacaine hydrochloride, 1 mg | 183 | $292 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 16 | $16 | None |
Who their Medicare patients are
644 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 11% · Women 67% · Also on Medicaid 14% · Health risk score 1.04. At or below the middle of the specialty; the typical sports medicine clinician is at 1.05.
Conditions among them: High blood pressure 61% · Coronary heart disease 21% · Depression 21% · Cancer 19% · Diabetes 18% · Chronic kidney disease 16% · Atrial fibrillation 13% · COPD 10% · Heart failure 8% · Stroke 6% · Dementia 4%.
The office billed $1,356,213, Medicare allowed $195,534 and paid $146,819; for 11,999 services of 45 kinds; $24,352 of it was for drugs given in the office and $122,468 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 644 | 11,999 | 75 | 1.04 | $1,356,213 | $146,819 |
| 2023 | 520 | 6,435 | 75 | 1.06 | $1,736,754 | $113,660 |
| 2022 | 538 | 4,986 | 74 | 1.00 | $1,661,604 | $100,557 |
| 2021 | 593 | 3,984 | 74 | 1.14 | $1,445,278 | $128,746 |
| 2020 | 506 | 3,837 | 73 | 1.09 | $1,081,491 | $98,855 |
| 2019 | 398 | 1,756 | 72 | 1.10 | $673,895 | $73,535 |
| 2018 | 77 | 252 | 74 | 1.21 | $88,870 | $12,732 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Return visit (30+ min) | 183 | $28,757 | $111 |
| New patient visit (45+ min) | 182 | $24,397 | $134 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 175 | $24,004 | $95 |
| Short return visit (20+ min) | 52 | $4,132 | $71 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | 12 | $3,999 | None |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 31 | $3,947 | $110 |
| Long return visit (40+ min) | 17 | $2,659 | $156 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 23 | $2,617 | $77 |
| Aspiration and/or injection of fluid from large joint | 31 | $1,775 | $46 |
| Injection of trigger points, 1-2 muscles | 14 | $1,165 | $51 |
| Ultrasonic guidance for needle placement | 30 | $1,010 | $27 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 148 | $892 | None |
| Injection into tendon or ligament | 11 | $793 | $47 |
| Telehealth originating site facility fee | 25 | $584 | $21 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 18 | $542 | $30 |
| Fluoroscopic guidance for needle placement | 16 | $517 | $25 |
| Injection, ropivacaine hydrochloride, 1 mg | 131 | $183 | None |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $84 | $4 |
| Injection, ketorolac tromethamine, per 15 mg | 16 | $18 | None |
2022: 18 services
| Return visit (30+ min) | 181 | $25,849 | $105 |
| New patient visit (45+ min) | 185 | $23,151 | $125 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 147 | $17,682 | $90 |
| Short return visit (20+ min) | 81 | $6,364 | $73 |
| New patient visit (60+ min) | 13 | $2,538 | $195 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 18 | $2,126 | $106 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 21 | $1,953 | $59 |
| Long return visit (40+ min) | 13 | $1,952 | $150 |
| Aspiration and/or injection of fluid from large joint | 34 | $1,861 | $47 |
| Ultrasonic guidance for needle placement | 40 | $1,015 | $24 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 126 | $705 | None |
| Injection into tendon or ligament | 12 | $657 | $51 |
| Telehealth originating site facility fee | 30 | $644 | $17 |
| Fluoroscopic guidance for needle placement | 11 | $296 | $25 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 15 | $275 | $18 |
| Injection, ropivacaine hydrochloride, 1 mg | 118 | $145 | None |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 13 | $80 | $5 |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $10 | None |
2021: 16 services
| Return visit (30+ min) | 241 | $39,450 | $112 |
| New patient visit (45+ min) | 270 | $37,105 | $137 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 123 | $14,433 | $93 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 52 | $6,771 | $104 |
| New patient visit (60+ min) | 30 | $6,126 | $204 |
| Long return visit (40+ min) | 30 | $4,895 | $158 |
| Short return visit (20+ min) | 45 | $3,062 | $67 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 22 | $1,976 | $60 |
| Aspiration and/or injection of fluid from large joint | 28 | $1,510 | $43 |
| Telehealth originating site facility fee | 41 | $1,059 | $20 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 13 | $664 | $44 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 93 | $557 | None |
| Ultrasonic guidance for needle placement | 18 | $504 | $27 |
| Fluoroscopic guidance for needle placement | 16 | $428 | $24 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $217 | $11 |
| Injection, ropivacaine hydrochloride, 1 mg | 86 | $121 | None |
2020: 17 services
| Return visit (30+ min) | 168 | $21,171 | $88 |
| New patient visit (45+ min) | 159 | $21,143 | $133 |
| New patient visit (60+ min) | 96 | $16,008 | $167 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 91 | $9,704 | $81 |
| Short return visit (20+ min) | 102 | $7,746 | $65 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 29 | $3,858 | $110 |
| New patient visit (30+ min) | 47 | $3,274 | $70 |
| Long return visit (40+ min) | 21 | $2,743 | $125 |
| Telehealth originating site facility fee | 78 | $2,056 | $21 |
| Aspiration and/or injection of fluid from large joint | 25 | $1,556 | $49 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 14 | $1,027 | $57 |
| Ultrasonic guidance for needle placement | 29 | $992 | $28 |
| Injection of trigger points, 1-2 muscles | 12 | $668 | $48 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 80 | $530 | None |
| Fluoroscopic guidance for needle placement | 12 | $362 | $26 |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 14 | $294 | $21 |
| Injection, ropivacaine hydrochloride, 1 mg | 80 | $110 | None |
2019: 13 services
| New patient visit (60+ min) | 161 | $28,545 | $177 |
| Return visit (30+ min) | 91 | $11,585 | $95 |
| New patient visit (45+ min) | 77 | $9,852 | $128 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 77 | $6,709 | $81 |
| New patient visit (30+ min) | 43 | $3,595 | $84 |
| Long return visit (40+ min) | 20 | $2,741 | $125 |
| Short return visit (20+ min) | 35 | $2,324 | $58 |
| Ultrasonic guidance for needle placement | 26 | $821 | $28 |
| Aspiration and/or injection of fluid from large joint | 17 | $723 | $43 |
| Aspiration and/or injection of fluid from medium joint using ultrasound guidance | 11 | $563 | $51 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 48 | $293 | None |
| Limited ultrasound scan of joint or other extremity structure except blood vessels | 11 | $220 | $20 |
| Injection, ropivacaine hydrochloride, 1 mg | 52 | $46 | None |
2018: 2 services
| New patient visit (45+ min) | 49 | $7,255 | $148 |
| New patient visit (60+ min) | 11 | $2,079 | $189 |
Drugs they prescribed that Part D paid
$2,753
Pharmacies billed $2,753 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
216 generic and fewer than 11 brand-name prescriptions · $2,753 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gabapentin | 93 | $1,083 | $12 |
| Lidocaine | 12 | $467 | $39 |
| Celecoxib | 18 | $427 | $24 |
| Methylprednisolone | 15 | $117 | $8 |
| Meloxicam | 40 | $75 | $2 |
Year by year
| 2024 | 217 | 94 | None | None | $2,753 |
| 2023 | 235 | 88 | None | 0% | $4,962 |
| 2022 | 421 | 121 | None | None | $10,245 |
| 2021 | 669 | 195 | 2% (11) | None | $18,645 |
| 2020 | 533 | 168 | None | None | $9,703 |
| 2019 | 175 | 83 | None | 0% | $2,238 |
| 2018 | 29 | 16 | 0% (0) | None | $702 |
| 2015 | 355 | 57 | 10% (36) | None | $15,852 |
| 2014 | 207 | 53 | 15% (30) | None | $9,205 |
| 2013 | 46 | 17 | None | None | $1,553 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Celecoxib | 38 | $2,288 | $60 |
| Gabapentin | 45 | $612 | $14 |
| Diclofenac | 16 | $447 | $28 |
| Meloxicam | 75 | $411 | $5 |
| Nabumetone | 15 | $291 | $19 |
| Methylprednisolone | 15 | $174 | $12 |
2022: 8 drugs
| Celecoxib | 74 | $4,734 | $64 |
| Diclofenac | 58 | $1,372 | $24 |
| Gabapentin | 90 | $1,241 | $14 |
| Baclofen | 15 | $1,064 | $71 |
| Meloxicam | 114 | $714 | $6 |
| Cyclobenzaprine | 13 | $290 | $22 |
| Methylprednisolone | 12 | $145 | $12 |
| Ibuprofen | 14 | $41 | $3 |
2021: 10 drugs
| Celecoxib | 127 | $7,208 | $57 |
| Diclofenac | 123 | $2,807 | $23 |
| Gabapentin | 140 | $2,331 | $17 |
| Meloxicam | 144 | $951 | $7 |
| Baclofen | 21 | $803 | $38 |
| Cyclobenzaprine | 25 | $478 | $19 |
| Nabumetone | 12 | $344 | $29 |
| Methylprednisolone | 18 | $135 | $7 |
| Tramadol | 11 | $39 | $4 |
| Diazepam | 14 | $14 | $1 |
2020: 6 drugs
| Diclofenac | 120 | $3,432 | $29 |
| Celecoxib | 57 | $2,200 | $39 |
| Meloxicam | 195 | $1,339 | $7 |
| Gabapentin | 66 | $859 | $13 |
| Nabumetone | 37 | $690 | $19 |
| Cyclobenzaprine | 12 | $94 | $8 |
2019: 5 drugs
| Celecoxib | 12 | $588 | $49 |
| Diclofenac | 17 | $410 | $24 |
| Meloxicam | 82 | $328 | $4 |
| Gabapentin | 16 | $168 | $11 |
| Methylprednisolone | 11 | $86 | $8 |
2018: 1 drug
| Meloxicam | 11 | $39 | $4 |
2015: 3 drugs
| Gabapentin | 25 | $313 | $13 |
| Oxycodone | 19 | $276 | $15 |
| Baclofen | 11 | $140 | $13 |
2014: 2 drugs
| Oxycodone | 12 | $166 | $14 |
| Gabapentin | 12 | $142 | $12 |
Money from drug and device companies
$82 in 2025
| 2025 | 2 | 3 | None | $82 |
| 2024 | 2 | 4 | None | $79 |
| 2023 | 1 | 5 | None | $794 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pacira Pharmaceuticals | Exparel | $44 | 2 payments
|
| Orthofix Medical | Physio-Stim | $38 | 1 payment
|
See all 3 published payments
| Pacira Pharmaceuticals | Meals · 2025-11-21 | Exparel | $27 |
| Orthofix Medical | Meals · 2025-06-18 | Physio-Stim | $38 |
| Pacira Pharmaceuticals | Meals · 2025-02-19 | Exparel | $17 |
See earlier years (2024, 2023)
2024: $79
| Pacira Pharmaceuticals | Iovera | $60 | 3 payments
|
| Ossur Americas | Miami J | $19 | 1 payment
|
2023: $794
| Pacira Pharmaceuticals | Iovera | $794 | 5 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1053654111
- Licence
- CA A158198, MO 2014014145California A158198: Current · expires 2028-08-31
- Trained
- University of Missouri, Columbia School of Medicine, 2013
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2081S0010X (2081S0010X); Federal specialty code 208100000X (208100000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-03-27
- NPI last updated
- 2024-04-27
- NPI record certified
- 2024-04-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1 Hospital Dr # Dc046.00, Columbia, MO, 65212 · 4625 Lindell Blvd Ste 420, Saint Louis, MO, 63108